---
title: "Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296183101.md"
description: "Nexgel, Inc. faces execution and integration risks from its $13.3 million acquisition of Celularity’s regenerative biomaterials license, with up to $20 million in contingent milestone payments. Failure to meet commercial expectations could strain resources and profitability. Despite these risks, Wall Street maintains a Moderate Buy consensus on NXGL stock based on one buy rating."
datetime: "2026-08-18T06:00:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296183101.md)
  - [en](https://longbridge.com/en/news/296183101.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296183101.md)
generator: "portal-rs"
---

# Nexgel’s Celularity Deal: Execution, Integration, and Profitability Risks from $13.3 Million Biomaterials Acquisition

Nexgel, Inc. (NXGL) has disclosed a new risk, in the Corporate Activity and Growth category.

### Summer Sale - Claim 70% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Nexgel, Inc. faces execution risk from its $13.3 million acquisition of Celularity’s regenerative biomaterials license, with up to $20.0 million in additional milestone payments contingent on commercial success. If BioNx-branded products fail to meet expectations or timelines, the company could incur substantial costs without commensurate returns.

Moreover, integrating Celularity’s products and technologies may strain Nexgel’s resources, diverting management attention from core operations and requiring further unplanned expenditures. Such complexity heightens the risk that projected synergies and growth from this transaction will not be fully realized, pressuring profitability and cash flow.

Overall, Wall Street has a Moderate Buy consensus rating on NXGL stock based on 1 Buy.

To learn more about Nexgel, Inc.’s risk factors, click here.

### Related Stocks

- [CELU.US](https://longbridge.com/en/quote/CELU.US.md)
- [CELUW.US](https://longbridge.com/en/quote/CELUW.US.md)
- [NXGL.US](https://longbridge.com/en/quote/NXGL.US.md)
- [NXGLW.US](https://longbridge.com/en/quote/NXGLW.US.md)

## Related News & Research

- [NXGL: Q2 revenue reached $3.69M with a $2.87M net loss; integration and expansion efforts continue](https://longbridge.com/en/news/296106108.md)
- [Workday stock is downgraded after buyout report as growth expectations are 'too optimistic'](https://longbridge.com/en/news/296104750.md)
- [Where will Workday stock be in 5 years if Silver Lake doesn't buy it?](https://longbridge.com/en/news/296091172.md)
- [Revive Therapeutics Outlines Strategy to Build a Biodefence and Pandemic Preparedness Therapeutics Portfolio | RVVTF Stock News](https://longbridge.com/en/news/296357987.md)
- [Clene Eyes Q4 NDA for ALS Drug After FDA-Requested Biomarker Analyses](https://longbridge.com/en/news/296405637.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**